Allianz Asset Management Gmb H Clovis Oncology, Inc. Transaction History

Allianz Asset Management Gmb H

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 13, 2020	SELL	$3.0 - $16.43 $94,308 - $516,493	-31,436 Closed	0 $0
Q3 2019 Nov 13, 2019	BUY	$3.93 - $15.35 $35,755 - $139,654	9,098 Added 40.73%	31,436 $125,000
Q2 2019 Aug 08, 2019	SELL	$12.81 - $25.67 $169,373 - $339,408	-13,222 Reduced 37.18%	22,338 $332,000
Q1 2019 May 13, 2019	BUY	$17.66 - $30.28 $627,989 - $1.08 Million	35,560 New	35,560 $883,000
Q4 2018 Feb 14, 2019	SELL	$11.63 - $32.67 $589,233 - $1.66 Million	-50,665 Closed	0 $0
Q3 2018 Nov 13, 2018	SELL	$29.37 - $49.48 $4.25 Million - $7.16 Million	-144,760 Reduced 74.07%	50,665 $1.49 Million
Q2 2018 Aug 13, 2018	SELL	$42.06 - $62.4 $218,838 - $324,667	-5,203 Reduced 2.59%	195,425 $8.89 Million
Q1 2018 May 14, 2018	SELL	$50.12 - $67.72 $1.99 Million - $2.69 Million	-39,663 Reduced 16.51%	200,628 $10.6 Million
Q4 2017 Feb 13, 2018	SELL	$57.69 - $84.58 $1.02 Million - $1.5 Million	-17,693 Reduced 6.86%	240,291 $16.3 Million
Q3 2017 Nov 13, 2017	BUY	$67.17 - $84.81 $7.79 Million - $9.84 Million	115,991 Added 81.69%	257,984 $21.3 Million
Q2 2017 Aug 14, 2017	BUY	N/A	105,455 Added 288.62%	141,993 $13.2 Million
Q1 2017 Apr 17, 2019	BUY	N/A	36,538	36,538 $2.33 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Allianz Asset Management Gmb H, based on Form 13F filings with the SEC.

Stay updated on Allianz Asset Management Gmb H with notifications on news.